Results 281 to 290 of about 308,418 (340)

Natural Products Targeting the EGFR/HER2 Axis in Tumorigenesis: Interpretation of Molecular Mechanisms and Recent Insights Into Synergistic Strategies for Cancer Therapy

Food Frontiers, EarlyView.
Schematic overview illustrating the anticancer mechanisms of selected natural products (resveratrol, quercetin, berberine) targeting EGFR and HER2 signaling pathways in tumor cells. These compounds inhibit receptor activation and downstream oncogenic cascades, including PI3K/Akt/mTOR, MAPK/ERK, and STAT3 pathways.
Iman Ramli, Anna Maria Posadino, Roberta Giordo, Antonio Barberis, Ylenia Spissu, Redouane Lemoui, William N. Setzer, Javad Sharifi‐Rad, Gianfranco Pintus   +8 more
wiley   +1 more source

Natural Products Targeting Notch Signaling in Cancer: Mechanistic Insights and Food‐Based Chemoprevention Potential

Food Frontiers, EarlyView.
The Notch signaling pathway plays a dual role in cancer, acting as both a tumor promoter and suppressor depending on cellular context. This review highlights how natural products modulate Notch signaling to inhibit tumor initiation, progression, angiogenesis, and cancer stem cell maintenance.
Rabab Fatima, Parteek Prasher, Mousmee Sharma, Dietrich Büsselberg, Gabriela Figueroa‐González, Octavio Daniel Reyes‐Hernández, Edgar Yebrán Villegas‐Vázquez, Hernán Cortés, Gerardo Leyva‐Gómez, Jesús Herrera‐Bravo, Solomon Habtemariam, Javad Sharifi‐Rad, Monica Butnariu, Cristian Berar, Angela Caunii, William C. Cho   +15 more
wiley   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

The role of cytokines in ovarian cancer drug resistance

International Journal of Cancer, EarlyView.
Abstract Ovarian cancer is the leading cause of death among women diagnosed with female reproductive system cancers. While significant advances have been made in treating various types of cancer, progress in ovarian cancer treatment over the past 20 years has been minimal, and the treatment course of ovarian cancer is not linear. Although many patients
Lu Wang, Yunxia Zang, Rebeka Dejenie, Junyuan Bing, Shixia Dong, Yanfei Zhang, Yi Zhu, Jingjing Li   +7 more
wiley   +1 more source

Adjuvant nivolumab after chemoradiotherapy and resection for patients with esophageal cancer: A real‐world matched comparison of overall survival

International Journal of Cancer, EarlyView.
What's New? Patients with esophageal or gastroesophageal junction (GEJ) cancer with residual disease after treatment with neoadjuvant chemoradiotherapy (nCRT) and resection frequently experience poor survival. Improvements in outcome, however, may be possible using adjuvant treatment with nivolumab.
Rob H. A. Verhoeven, Steven C. Kuijper, Marije Slingerland, Bas Wijnhoven, Mark I. van Berge Henegouwen, Peter S. N. van Rossum, Sarah Derks, Bianca Mostert, Nadia Haj Mohammad, Hanneke W. M. van Laarhoven   +9 more
wiley   +1 more source

Clinical validation of a DNA methylation biomarker associated with overall survival of relapsed ovarian cancer patients

International Journal of Cancer, EarlyView.
What's New? Most patients with ovarian cancer (OC) relapse after first‐line chemotherapy, and prognosis with second‐line treatment depends largely on the platinum‐free interval. However, reliable biomarkers to predict response to second‐line therapy remain lacking.
Muhammad Habiburrahman, Nahal Masrour, Naina Patel, Anna M. Piskorz, Robert Brown, James D. Brenton, Iain A. McNeish, James M. Flanagan   +7 more
wiley   +1 more source

Targeting the ST3 beta‐galactoside alpha‐2,3‐sialyltransferase 1 (ST3Gal1) as a potential therapeutic strategy to overcome anti‐VEGF resistance in endometrial cancer

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To investigate the role of ST3 beta‐galactoside alpha‐2,3‐sialyltransferase 1 (ST3Gal1) in endometrial cancer (EC) progression and its potential as a therapeutic target to enhance the efficacy of antiangiogenic treatment. Methods ST3Gal1 expression and its clinical relevance were analyzed in EC tissues.
Chia‐Hao Liu, Szu‐Ting Yang, Wei‐Ting Chao, Chen‐Hao Lin, Yu‐Chieh Lee, Chiung‐Ru Lai, Shie‐Liang Hsieh, Liang‐Wei Wang, Peng‐Hui Wang   +8 more
wiley   +1 more source

Revisiting intraperitoneal chemotherapy for advanced high‐grade serous ovarian cancer

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To compare overall survival (OS) in patients with high‐grade serous ovarian cancer (HGSOC) treated with intraperitoneal (IP) chemotherapy versus intravenous (IV) chemotherapy. Methods A retrospective study of Stage III HGSOC with optimal primary cytoreduction during 2007–2019, followed by adjuvant IP or IV chemotherapy.
Joshua S Cheruvathur, Gabriel Levin, Reitan Ribeiro, Florentin Racovitan, Joanne Power, Xing Zeng, John Sampalis, Lucy Gilbert   +7 more
wiley   +1 more source

Minimally invasive surgical treatment of recurrent endometrial carcinoma: A systematic review

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Background While the role minimally invasive surgery (MIS) is established for primary endometrial carcinoma (EC), its feasibility in recurrent cases remains underexplored. Objective To systematically review the literature about MIS for EC recurrence.
Antonio Raffone, Daniele Neola, Alessio Colalillo, Claudia Tucci, Diego Raimondo, Antonio Travaglino, Maria Giovanna Vastarella, Massimiliano Fambrini, Maurizio Guida, Silvia D'Ippolito, Renato Seracchioli, Luigi Cobellis, Francesco Cosentino   +12 more
wiley   +1 more source

The combined influence of microbiome and soil environment contributes to the chemotype differentiation in Atractylodes lancea

iMetaOmics, EarlyView.
Genetic differentiation between the Maoshan‐Dabie Mountains group (MA genotype) and Qinling‐Taihang Mountains group (SA genotype) of Atractylodes lancea occurs along altitude and climatic gradients. High altitudes and their corresponding climatic conditions favor the formation of SA, while low altitudes and their corresponding climatic conditions favor
Hongyang Wang, Zheng Peng, Chengcai Zhang, Chuanzhi Kang, Yan Zhang, Xiuzhi Guo, Yiheng Wang, Guang Yang, Zengxu Xiang, Li Zhou, Zhixian Jing, Dahui Liu, Sheng Wang, Luqi Huang, Lanping Guo   +14 more
wiley   +1 more source